9 October 2014
Researchers from the University of California, Los Angeles (UCLA) found that a drug that is currently used to treat another disease could help slow down the progression of Parkinson's.
Published in the latest edition of the journal Neurotherapeutics, found that a drug called AT2101, which is currently used for Gaucher disease, was able to improve motor function, stop inflammation in the brain and reduce levels of alpha-synuclein - a critical protein for Parkinson's - in mice.
Although the root cause of the disease is unknown, it is widely thought that high levels of alpha-synuclein play a significant role as it has been found in all people with the disorder. It is assumed that the protein is able to destroy neurons in the brain that create dopamine - therefore stopping it from regulating a number of functions such as movement.
"This is the first time a compound targeting Gaucher disease has been tested in a mouse model of Parkinson's disease and was shown to be effective," said the study's senior author, Marie-Francoise Chesselet, the Dr Charles Markham, professor of Neurology at UCLA and director of the UCLA Center for the Study of Parkinson's Disease.
Posted by Edward Bartel
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.